Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06031441 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 18
- Study locations
NCT06031441: Recruiting Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors, sponsored by Genentech.
NCT06031441 is a Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors that is actively recruiting participants, run by Genentech. The registered enrollment target is 250 participants, above the 194-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (29% higher). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06031441, a Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG RO7566802
Study Locations (18)
Other
- National University Hospital - Singapore
- National Cancer Centre - Singapore
- Addenbrooke's Hospital - Cambridge
- Leicester Royal Infirmary - Leicester
- St Bartholomew's Hospital - London
- Sarah Cannon Research Institute - London
- Churchill Hospital - Oxford
- The Royal Marsden hospital - Sutton
Alabama
- University of Alabama at Birmingham (UAB) - Birmingham
Connecticut
- Yale Cancer Center - New Haven
New York
- Icahn School of Medicine at Mount Sinai (ISMMS) - New York
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Magee-Woman's Hospital - Harrisburg
Tennessee
- SCRI Oncology Partners - Nashville
New South Wales
- St Vincent's Hospital Sydney - Darlinghurst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06031441 shows while recruiting
NCT06031441 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 194-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (29% higher).
The record links to 3 conditions, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT06031441 lists 18 locations in 11 states (Other, Alabama, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06031441 about?
NCT06031441 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants ...
What is the current status of trial NCT06031441?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2023-11-27. Estimated completion is 2027-12-31.
What conditions does trial NCT06031441 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors, Locally Advanced Solid Tumors, Recurrent Solid Tumors.
What interventions are being tested in trial NCT06031441?
The interventions under investigation include: Atezolizumab (DRUG), RO7566802 (DRUG).
Who is sponsoring clinical trial NCT06031441?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06031441 being conducted?
This trial has 18 study locations across Alabama, Connecticut, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06031441's enrollment target sits among peer trials
250 7th of 20 higher than 14 of 20 other Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI